Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Core Insights - Xenon Pharmaceuticals Inc. announced equity inducement grants to four new non-officer employees, totaling 78,600 share options and 1,800 performance share units (PSUs) [1][2] - The share options have an exercise price of $38.28 per common share, equal to the closing price on the grant date, and will vest over four years [2] - The company focuses on developing therapeutics for high unmet medical needs, particularly in areas like epilepsy and depression, with a notable product, Azetukalner, in late-stage clinical development [3] Summary by Category Equity Inducement Grants - The grants consist of 78,600 share options and 1,800 PSUs, approved by the Compensation Committee of the Board of Directors [1] - The share options vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting monthly [2] - Each option has a 10-year term and is subject to the terms of the 2025 Inducement Equity Incentive Plan [2] Performance Share Units - The PSUs will vest based on the achievement of predefined milestone-based objectives over a three-year performance period [2] - Each PSU grant is also subject to the terms of the performance share unit award agreement and the 2025 Inducement Equity Incentive Plan [2] Company Overview - Xenon Pharmaceuticals is dedicated to discovering and developing life-changing therapeutics, focusing on neuroscience [3] - The company is advancing an ion channel product portfolio to address significant medical needs, including epilepsy and depression [3] - Azetukalner is highlighted as a leading product in late-stage clinical development for multiple indications [3]